Breast Cancer Breakthrough - Prof Andrew Tutt On The Olympia Trial

Breast Cancer Breakthrough - Prof Andrew Tutt on the OlympiA trial

The Institute of Cancer Research, London

Prof Andrew Tutt - Biomarkers for hormone therapy resistance & deficiency, & targeting BRCA1/2

Breast Cancer Trials

Breast Cancer Breakthrough - Professor Chris Lord on the OlympiA Trial

The Institute of Cancer Research, London

Prof Andrew Tutt: first targeted treatment for hereditary cancer | King's Health Partners 10 Years

King's Health Partners AHSC

ASCO 2021 - Highlights on shifting PARPi to Early Breast Cancer: The OlympiA study

European Society for Medical Oncology (ESMO)

How Breast Cancer Now helped discover PARP inhibitors

Breast Cancer Now

The OlympiA Breast Cancer Clinical Trial - Breast Cancer Trials

Breast Cancer Trials

ASCO Daily News 2021 Plenary Update - LBA1: OlympiA

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer wit...

Breast cancer breakthrough

OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer

Perspectives on the OlympiA study of adjuvant olaparib in early breast cancer | Nadine Tung

Medicine Matters oncology

2022 Breakthroughs & Discoveries Panel

Basser Center for BRCA

ASCO 2009: PARP inhibitors show promise for hard-to-treat breast cancers

OlympiA: adjuvant olaparib following chemo significantly improves IDFS

Discover the Breakthrough Treatment Protocol for ER+ Breast Cancer! Here's What You Need To Know

The importance of the OlympiA trial for breast cancer patients

Clinical Trials and Advances in Breast Cancer Therapy at Northwestern Medicine

Breakthroughs for Physicians

An overview of recent metastatic HER2+ breast cancer trials